Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope Sleuth or someone else gets a hold of that CNN Int. piece to watch it.
Again, a brilliant move by CWEB and CVSI marketing should do something because the situations is really bad right now.
I think that there was a Dr. Oz and Sanja G. CBD combo presentation where CVSI came into the scenes last year.
But YES CVSI marketing dept. must wake the F up!!!! and start thinking outside the box.
Very smart move. But there are too many and more important regulatory hurdles to overcome.
CWEB took center stage but the public is drawn to the compound. I am sure that CVSI will benefit from this indirectly too. The same thing will happen when CVSI does the same, all the top companies will benefit.
I was thinking that none of this FDA non-sense is good, but CSVI has been at the forefront and center stage dealing with the problem. That's some serious publicity too.
FDA must feel by now that CVSI is the industry standard in the supplement lane that they have to deal with.
And if we are successful, all producers will benefit too.
Anything that supports the industry right now is good. IMO
Super. Great find, thanks. Great CRN stance on CBD regulations.
CV Sciences, Inc. Appoints Dr. Douglas MacKay as Senior Vice President of Scientific and Regulatory Affairs
LAS VEGAS, March 01, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of industry-dominating hemp CBD brand, PlusCBD OilTM, today announced the appointment of Douglas “Duffy” MacKay, N.D., as Senior Vice President of Scientific and Regulatory Affairs, effective March 18, 2019. Dr. MacKay will oversee the Company’s scientific and regulatory affairs department, ensuring CV Sciences continues to pioneer the development of hemp-based cannabidiol (CBD) products driven by rigorous science, innovation, and regulatory compliance.
Dr. MacKay brings more than 20 years of experience to CV Sciences in nutrition research, dietary supplements, health sciences and regulatory affairs. He joins CV Sciences following more than ten years at the Council for Responsible Nutrition (CRN), most recently serving as Senior Vice President of Scientific and Regulatory Affairs. CRN is the leading trade association representing dietary supplement and functional food manufacturers and ingredient suppliers, with a mission to sustain and enhance a climate for its members to responsibly develop, manufacture and market dietary supplements, functional food and nutritional ingredients.
“Dr. MacKay is renowned in the fields of natural medicine, nutrition and public policy, and his background and leadership capabilities make him the ideal person to lead our scientific and regulatory team,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “CV Sciences is dedicated to accelerating CBD innovation, and imperative to that commitment is our ability to attract the world’s best talent. Employing people with the caliber of Dr. MacKay allows CV Sciences to not only strengthen our position as a provider of high- quality CBD products, but also improves the knowledge base and credibility of the overall industry through advanced understanding of research, product, and technology development, while ensuring regulatory compliance.”
Dr. MacKay’s responsibilities at CRN included providing scientific expertise in nutrition, pharmacology, pharmacognosy, toxicology, for evaluating proposed government and industry actions; building effective rapport with scientific communities; establishing working relationships with regulators through engagement on dietary supplement and functional food regulatory matters; and educating regulators, legislators, and Attorney Generals regarding industry self-regulatory and compliance initiatives. Prior to CRN, Dr. MacKay served as Research Advisor to Nordic Naturals, the leading omega-3 fish oil brand in the United States.
“I have dedicated my career to advancing the research, science and development of nutritional products and supplements, and joining CV Sciences presents an exciting opportunity to continue to move the CBD industry forward through credible scientific rationale,” said MacKay. “CV Sciences is a clear leader in hemp-based CBD and I am very pleased to join the management team to further advance their mission to help people maintain a healthy lifestyle through continued innovation of the PlusCBD Oil product line.”
Dr. MacKay serves on the advisory board for the American Botanical Council, the NSF International Joint Committee on Dietary Supplements, and the NIST/NIH Dietary Supplement Laboratory Quality Assurance Program. He is a licensed naturopathic doctor and previously was owner and practitioner in a New Hampshire-based integrative medical practice. Additionally, Dr. MacKay is on the editorial board of three peer-reviewed publications: the official publication of the American Association of Naturopathic Physicians, Natural Medicine Journal, Integrative Medicine—a Clinician’s Journal, and Current Topics in Nutraceutical Research. Dr. MacKay is also Chair of the Steering Committee for the SIDI Work Group.
Dr. MacKay holds a bachelor’s in Marine Biology from the University of California, Santa Cruz and his N.D. from the National College of Natural Medicine in Portland, Oregon.
https://www.securingindustry.com/electronics-and-industrial/porsche-says-counterfeit-parts-market-is-booming-/s105/a10528/#.XeCQ0i1DmRs
Porsche says counterfeit parts market is ‘booming’
Luxury carmaker Porsche has revealed that it confiscated more than 200,000 counterfeit goods with a value of almost €60m last year, even tracking producers back to rural China.
The haul including 33,000 car parts worth more than €2m, according to a post on the company’s website which describes the actions taken by its three brand protection officers to try to curb the trade.
There is a particular demand for wearing parts, which need to be replaced more often and can be sold for a much higher price if they bear the Porsche emblem on the packaging, it says.
That includes products like wheel centre caps, air filters and rims, as well as airbags and brake discs which are particularly concerning as they could end up compromising consumer safety.
A lot of the counterfeits are sold on online platforms such as Amazon, eBay or Alibaba, says Porsche, while there are also a lot of promotional items – baseball caps, T-shirts and sunglasses for example – at trade fairs.
“Sometimes the counterfeits are quite obvious,” explains Michaela Stoiber, one of the brand protection officers.
“The products are far cheaper than normal, or the Porsche emblem has been poorly copied. We sometimes also find that a different animal is shown in the centre of the logo. For example, instead of the Porsche horse, it could be a sheep standing on its hind legs.”
On one occasion Stoiber impounded thousands of erectile dysfunction pills shaped like the Porsche emblem from Turkey, which gives an indication of the lengths counterfeiters will go to in order to cash in on someone else’s trademarks.
Most of the counterfeits – an estimated 80 per cent – originate in China, with production facilities ranging from tiny workshops to large-scale factories. The city of Shenzhen is one of the hotspots for the trade, says Porsche.
The carmaker is also seeing evidence of the often-reported change in the shipping tactics of counterfeiters, with more and more shipments being sent in small parcels – rather than large containers – to frustrate enforcement efforts.
Thanks SL. I know that you follow my reasoning about the possible outcome.
There are some heavy weights among CRN members, politicians (farmers) and the whole industry including regular CBD consumers for the FDA to stand a chance.
I'm OK man. I always have bigger things to worry about.
I don't get mad for little things that easily any more. Took a lot of practice.
Talking about wifes now. That's VERY LOW.
Just confirmed your expertise. Good nite.
You should know...Good luck with your expertise. I knew you had to be good at something.
READ MY LIPS:
WATCH HOW THE LEADERS FIX THINGS AND TURN ALL THIS MESS AROUND.
Ok you won. You know more that Stuart Tomc and Duffy MacKay put together. Only 3 to 4 decades of dealing with the FDA between the 2 of them. Both come from the Nordic Natural Fish Oil successful company. One served as CEO of the CRN for years before joining CVSI.
Tomc's job is to read every scientific paper ever written about CBD that he can get his hands on. Have you ever watch one of his presentation. You will be surprised of the energy this person displays when he is teaching. And he only keeps getting better.
And the CRN is the private organization that deals directly with the FDA in everything that is supplements.
I GUESS THEY BOTH FAILED
AND YOU WON.
Same goes for your buddy.
LONG CVSI
https://www.crnusa.org/membership-member-center/member-companies
JUST A FEW:
Voting Members
Abbott Nutrition
ACG North America
Activ Nutritional, LLC (Adare Pharmaceuticals)
AdvoCare International, L.P.
Amway/Nutrilite
Arbonne International, LLC
Archer Daniels Midland Company
Atrium Innovations, Inc.
Avon Products Inc.
Balchem Human Nutrition & Pharma
Barrington Nutritionals
BASF Corporation
Bayer HealthCare LLC
BEFORE Brands, Inc.
Bergstrom Nutrition
Bifodan
BIO-CAT, Inc.
BioCell Technology, LLC
Biotron Laboratories, Inc.
Brassica Protection Products LLC
CV Sciences
Care/Of
Cargill Health & Nutrition
Catalent
Cepham Inc.
Chemi Nutra
Chr. Hansen, Inc.
ChromaDex
Church & Dwight Co. Inc.
The Clorox Company
Colorcon
Country Life Vitamins
Cypress Ingredients
Deerland Probiotics & Enzymes
doTERRA International
Douglas Laboratories
DSE Healthcare Solutions, LLC
DSM Nutritional Products
Elysium Health
Embria Health Sciences
Evolva Nutrition, Inc.
Functional Remedies, LLC
Ganeden, Inc.
And you think that's good for CWEB or any other company? If CVSI has any problems, imagine when CWEB presents it's hybrid strain. Or they probably NEVER do it because of the FDA stance. Or most likely is in the process. A huge disappointment for all but just in the mean time.
You need to understand that someone has to break through for the rest to follow. Producers need to know that is possible, doable in order to invest and have such a great certification.
If you spend some time reading about GRAS you would know that the certification represents a specific ingredient or compound for a specific intended use.
When the FDA talks about CBD GRAS they mean a general recognition to the ISOLATE form and NOT a specific product. No body will pursue such a GRAS status because is drug ingredient.
We have experts in these matters onboard . The CRN, CVSI, CWEB through the HEMP Round Table and other Hemp organizations are the same right now.
Just check how many companies the CRN represents. Duffy MacKay is Ex-CEO of CRN.
And the FDA is being negligent and incompetent by having so much CBD trash on the shelfs.
All these PRs coming out from the different organizations is just a slap in the face. The FDA is looking terrible right now. How much pressure can they hold. I don't think that will be much.
There are plenty politicians behind these companies, bigger than CVSI and CWEB and the rest put together. Just watch and learn how a true leader turns this whole mess around. Or how do you think that the Hemp Act got included in the Farm Bill in the first place.
Pay attention.
Long CVSI
Great info Sleuth, as always. Thanks.
Thanks for you post Marty. Happy TG for all those who posted best wishes.
The FDM channel is self enforced because of the very high entry barrier .
Another thing is that it's good that the financial sector is already onboard like the BofA.
That's more pressure for the FDA from the financial sector and connections to get this resolved.
If the SAFE banking act passes is another one that will add to the pressure on top f the farmers, the Senate, producers, retailers, comsumers. Everybody.
The fact that the SP are bouncing a bit for the main pakyers is a sign that the market is betting on the PRESSURE the FDA has and the players involved like Senator MM.
The FDA hinted that they know how to resolve it but they need arrangements. Whatever that is.
I bought the dip during the last 2 trading days because I changed my outlook about the regulations. I was negative at first (few weeks ago) but after seen how many associations and the broad support for the cannabis plant known as HEMP, I am betting on this problem getting resolved sooner than later.
Everybody needs to prepare of a couple of flat or bad quarters just in case.
Or exit and return when things become clear. Depends on each person tolerance.
The advantages of CVSI in an irregular market are plenty. And it seems like the FDA is going to get tough no matter what they decide. That should give us at least a couple of flat quarters to start or better.
The 500% Expansion is done.
Enough CASH for the next 18 months at least.
Efficient operation: Always, in good and rough times. Flexibility is paramount right now.
Automatic sales systems in place.
Contract with domestic farmers (custom planted) ready.
I expect some customer loyalty due to the effectiveness of the product at great prices.
Those who left, most will return.
Facing and dealing directly with the FDA in the good , the bad and the ugly. The ONLY company facing the current hurdles.
New products and labels coming out.
New scientific studies should come out soon making the brand stronger and FDA regs. ready.
Some good things happening in the legal front (lawsuit). More new next week.
The pharma segment got a green light with the patent being appealed. Studies to commence next year in Europe.
Political connections. The same that got the Hemp Act included in the 2018 Farm Bill.
How many companies can make such a list.
In a brief interview on the sidelines of the STAT Summit in Boston on Thursday, Abernethy, who serves as the principal deputy commissioner of the FDA and the head of the agency’s CBD working group, acknowledged those frustrations, but insisted the agency is going as fast as possible.
“My commitment is to work as quickly as possible and I’ve made that commitment quite vocally,” Abernethy said. “There is a great sense of urgency internally to get this out.”
At the same time, Abernethy declined to telegraph any significant action from the agency any time soon — particularly on a long-awaited report that would outline the FDA’s current thinking on the issue, which Abernethy previously tweeted would be released by “end of summer/early fall.”
“I’d love to give you an exact time frame,” Abernethy said. “I will say that it is not because we’re not trying. And actually, this is not about needing to get something written. Think about all the different agreements you’ve gotta get.”
In response to the agency’s inaction, industry and consumer groups have launched pressure campaigns against the agency, even threatening to get Congress involved.
“Something has to change,” said David Spangler, the top policy official for the Consumer Healthcare Products Association. “I’m at a loss for why they have not [acted faster].”
https://www.statnews.com/2019/11/22/fda-regulation-cbd-amy-abernethy/
Great. The tougher the regulations (if any) the better for CVSI.
The problem then will be the capacity to enforce. If retailers feel the pressure, they will reduce the numbers of suppliers.
By when then? Mid December?
I think that the FDA fumbled the ball with the Epidiolex/Clobazam issue. They are holding the industry hostage with that drug when things are NOT so clear. In the studies used to approve Epidiolex, the new drug was always used in combination with Clobazam. They could be asked to clarify what happened there. They will be pressured to comply with the industry and issue interim regulations.
Politicians are experts finding weak spots.
CVSI expansion is done. Implementation of new automatic systems for better sales management is done.
New contracts with farmers are in place. All we need is a little break from the FDA and things can spin around next year.
I think it will get resolved. No one is buying the FDA BS campaign. The SP reaction yesterday proved that.
Long CVSI
Christmas tree shortage possible as farmers switch to hemp
Farmers moving to hemp production could cause shortages of other crops, including Christmas trees.
Consumers should make their yearly pilgrimage to pick out the perfect tree for the holidays sooner than later, according to experts, because some tree farmers have pivoted away from the crop to concentrate on faster-growing, more profitable crops such as hemp.
One Texas tree wholesaler saw his order cut by 30% this year, John Patton of Patton Christmas Trees in Dallas told CBSDFW.com.
The biggest shortage is for larger trees, 8 feet and taller. The later timing for Thanksgiving could also cause consumers to lose out on trees this year.
More details about the Christmas tree shortage are available here.
CVSI started in the 20 cents range without much cash. Full organic growth to the $58M sold in products in the last 12 months and $14.2M CASH available.
CWEB raised lots of cash and started at $7.00.
Two VERY different stories.
2 Very different products.
2 Clery different business models.
2 very different results long term.
One has proven that you can grow and make money with dilution.
Both need regulations. The TAM is the same for both if the regulation favors BOTH.
a 4,000 difference in stores is nothing when you have 200,000 stores available market.
Let's see one year from now.
At $25M sales, CVSI would be making about $3-$4M i profits, NOT loosing money.
Be fair and post the same chart for CWBHF...
Let's see what happens one year from now.
CWBHF all tea leafs. Please lead your people. LOL.
Thanks for your concern but you don't need to worry about my investment. I am UP even after the current industry dilema. Since I am a long investor, I can wait for regulations to come whenever they come.
I was invited to this board so I came and took a closer look at the numbers. I was planning to invest in CWEB a few months back but after studying the financials and the different business models I m happy holding CVSI. Cal me crazy but I am also a contrarian and I follow the performance and not the SP.
I will show what I mean:
CWEB made $71.8 Millions in sale this year so far. And cost the company $24.8 Millions in CASH.
With over 9,000 stores and a good E-Commerce platform.
CVSI made $44.4M in sales and has MADE $2.4 M in CASH.
With 5,400 stores .
So thanks but I feel very confidente I own the BEST company going forward.
True financial leaders MAKE MONEY.
The FDA regulations will signal the START.
Be aware of the Canadian growers joining the race and their failed business model.
Then please tell me what's CWBHF 3 months trend????
Watch closing how it continues trending down in the next 3 months....
Will CWEB break the $12.50 - $13.00 range????
Under $7.00 in a couple of months.
At CWBHF.......Who needs VISION when you can read the numbers.
CASH in hand was crashing. VERY TRUE. Dilution coming, and there will be more if the FDA persist in their current position. And even if they open up the rules to sell, they will be VERY HARSH for Hybrid growers with transparency problems. What's in YOUR PRODUCTS?????
BTW, Is CWEB on the TABLE???? Will it be?????? Where are your FDA EXPERTS???????
Can't speak the language then you are bound to FAIL.
BUY THE FAT PIG.
CWBHF. You get confortable and keep buying that CWEB PIG, THAT HAS NO LEADERSHIP.
FAKE GUIDANCE ALL ALONG. THE INDUSTRY IS CRASHING IN YOUR FACE AND YOUR MANAGEMENT SAYS SQUAT.
LOAD UP WITH CASH BECAUSE YOU ARE GOING TO NEED IT.
CWEB NEEDS TO SHOW SOME LEADERSHIP
Where is CWEB PR or announcement about the FDA PR yesterday??? Where is you management hiding???
When people buy PlusCBD they know what they are buying. Compound and content information is VERY available BEFORE you buy.
It's NOT THE SAME for CWEB.
CWEB needs to change it's marketing, label, hire someone that speaks the FDA language. Be a "So Called" Industry Leader and show up to the industry's fights.
When things get tough, CWEB never shows it's face. FAILED as a LEADER.
Read the following:
https://www.nutraingredients-usa.com/Article/2019/11/25/Watch-this-case-11th-Circuit-concludes-adulterated-supplements-are-worthless-and-this-economic-loss-is-sufficient-to-sue?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright
Dear Valued Partner,
We’re reaching out to address the FDA’s recent Consumer Communication and Warning Letters related to CBD. CV Sciences supports their enforcement actions against companies who make unsubstantiated claims that CBD containing products can treat cancer, Alzheimer’s disease, opioid withdrawal, etc. These companies put consumers at risk, while giving responsible companies, who have done their due diligence, a black eye.
That said, we are disappointed in the alarmist tone used by the FDA in their consumer update, which was released simultaneously with the Warning Letters, regarding the safety of CBD, in that they did not differentiate the vast range of products, servings, and ingredient forms. We agree with the FDA in that there are currently products that raise safety concerns due to their high levels of CBD or that are being marketed to children. As an industry leader, CV Sciences has conducted scientific studies (CVSI GRAS + J. Toxicology) on our specific hemp extract, made through a proprietary process, and considered the levels of CBD and our target consumer population to determine a safe amount that raises none of the potential health risks identified by FDA.
At CV Sciences, consumer safety is our top priority. The FDA stated that it cannot conclude that CBD is generally recognized as safe (GRAS) and this is because a GRAS affirmation is directly linked to a specific ingredient and conditions of use (serving size, age restrictions, etc.). To this point, we can share our research that supports the safety of our specific ingredients for our intended consumer. We believe that the FDA’s statements that CBD is not GRAS are directed toward companies that have piggy-backed on our research, without addressing the significant differences in ingredients, products, levels of CBD and serving size recommendations.
Furthermore, we advocate that the industry limits CBD to dietary supplements and topical products only—not as a food additive. We took this stance at the May 31, 2019 FDA public meeting and continue to support it. We’re optimistic that the FDA shares our goal to create a clear, regulatory path for science-based, hemp-derived CBD ingredients as dietary supplements, that provide an appropriate and safe level of CBD. Lastly, we welcome the opportunity for the FDA to draft regulation allowing for CBD as a dietary supplement, provided the industry, as a whole, responsibly steps up with sound science and research.
Questions? I’m available to address all of the above and to provide further clarification. Please contact Anissa Medina to schedule a call: anissa.medina@cvsciences.com.
When people buy PlusCBD they know what they are buying. Compound and content information is VERY available BEFORE you buy.
It's NOT THE SAME for CWEB.
CWEB needs to change it's marketing, label, hire someone that speaks the FDA language. Be a "So Called" Industry Leader and show up to the industry's fights.
When things get tough, CWEB never shows it's face. FAILED as a LEADER.
Read the following:
https://www.nutraingredients-usa.com/Article/2019/11/25/Watch-this-case-11th-Circuit-concludes-adulterated-supplements-are-worthless-and-this-economic-loss-is-sufficient-to-sue?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright
7.5 Millions shares.
CVSI does NOT need to dilute it's stock for the next 18 months or more.
If needed R&D will be scaled back a bit. About $4M a year can be saved in R&D and still spend more than CWEB.
I sincerely hope that CVSI starts printing GRAS on the labels SOON to see what happens..
It's time to challenge the FDA and find out WTF is going to happen.
CVSI has been selling PlusCBD for more than 5 years and the reports of adverse effects are minimum. It's all BS.
All these data was given to the FDA in June after the hearing. 4 or 5 companies provided their data for them to see and analyze. The other companies had the same results, all good. They have NO excuse.
If they can't make any positive claims, then they shouldn't be making any negative either because there is NON for any top CBD (FSHE) supplement.
What they are doing is irresponsible and IMO, illegal.
But things can turn on a dime if they give ANY kind of guidance. They would be endorsing CBD and they will be contradicting themselves. No one will be surprised.
I am personally counting of the tremendous NEED there is for this kind of compound. If there is something toxic everywhere right now is the current lifestyles 7X24X365 full of the silent killer; "STRESS". Stress has made a lot of peole sick every day.
And like they say, the gene is out of the bottle, farmers, producers, retailers, consumers and the whole value chain are waiting. Everybody is INTO this movement. I think it is hard to stop but investors will have to stretch their outlook in the mean time. Damages can only be evaluated a year after any regulations are given.
BTW, I am sure that CVSI CEO will release a PR once the FDA gives its UPDATE on their plans in the next couple of weeks.
Do you see CVSI on the 15 companies list????
Is the FDA talking about CBD ISOLATE every time they release a PR?
Because their statement is correct, they can NOT find CBD "ISOLATE" as a GRAS compound because no one has done the work for it's intended use as a food ingredient or supplement, and no one will.
In other words: IMO, FDA. CBD is ISOLATE and they are damaging the industry by making such references without being sure if it works or NOT.
If they are not sure that CBD is safe, the they are ALSO NOT sure that it is toxic in low dosages, but they keep hitting the nail on the head about the topic. Everybody has to make their own decision about what's going to happen in the next 6 to 9 months.
Does CVSI PR the full portfolio expansion deals ???
Is CVSI planning to print GRAS on the labels of all the products???
How does GRAS is obtained and what's it's purpose? WHAT IS GRAS FOR???
Maybe if you spent more time reading instead , you could be more confident in your trading.
Just saying and these are the questions I ask myself
Long CVSI
Thank you very much for your honest reply. I understand your position.
My respects.
Can you tell us what's the reason for the delay. I am talking about the 10K & Q reports. Do you know anything about this?
Please shed some light into this situation if you have any information.
Take a look a the last 10K report and look for "legal proceedings".
It goes back a couple of years.
Blockchain: Interesting numbers.
You raise money when you need it. And CWEB will need plenty. I know a company that does not need CASH because of it's efficient business model and financial discipline and strategy.
Care to guess???